Corcept Therapeutics Inc
NASDAQ:CORT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
21.1
59.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CORT stock under the Base Case scenario is 63.25 USD. Compared to the current market price of 57.54 USD, Corcept Therapeutics Inc is Undervalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Corcept Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CORT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Corcept Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Corcept Therapeutics Inc
Balance Sheet Decomposition
Corcept Therapeutics Inc
Current Assets | 467m |
Cash & Short-Term Investments | 380.3m |
Receivables | 59.7m |
Other Current Assets | 26.9m |
Non-Current Assets | 317.3m |
Long-Term Investments | 167.3m |
PP&E | 8.4m |
Other Non-Current Assets | 141.5m |
Current Liabilities | 126.2m |
Accounts Payable | 18.6m |
Accrued Liabilities | 107.6m |
Non-Current Liabilities | 19.2m |
Other Non-Current Liabilities | 19.2m |
Earnings Waterfall
Corcept Therapeutics Inc
Revenue
|
628.6m
USD
|
Cost of Revenue
|
-9.8m
USD
|
Gross Profit
|
618.8m
USD
|
Operating Expenses
|
-475.4m
USD
|
Operating Income
|
143.4m
USD
|
Other Expenses
|
-1.5m
USD
|
Net Income
|
141.8m
USD
|
Free Cash Flow Analysis
Corcept Therapeutics Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Corcept reported $182.5 million in revenue, up 48% year-over-year, raising its 2024 guidance to $675-$700 million. The company is advancing its proprietary drug, relacorilant, which showed significant improvements in managing Cushing syndrome, achieving better hypertension and glucose control. Patient responses were statistically meaningful, with systolic blood pressure improvements of 6.6 mmHg. Corcept anticipates FDA submission for relacorilant by year-end, further supported by substantial growth potential from increased awareness of Cushing syndrome. They aim to become a $3 billion business within five years, bolstered by trials in oncology and metabolic diseases.
What is Earnings Call?
CORT Profitability Score
Profitability Due Diligence
Corcept Therapeutics Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Score
Corcept Therapeutics Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
CORT Solvency Score
Solvency Due Diligence
Corcept Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Corcept Therapeutics Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CORT Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CORT is 76.4 USD with a low forecast of 67.67 USD and a high forecast of 84 USD.
Dividends
Current shareholder yield for CORT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CORT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 238 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The company has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.
Contact
IPO
Employees
Officers
The intrinsic value of one CORT stock under the Base Case scenario is 63.25 USD.
Compared to the current market price of 57.54 USD, Corcept Therapeutics Inc is Undervalued by 9%.